How blocking androgen receptors affects T cell function in cancer patients
Official title: Effects of androgen receptor antagonists on human T cell function
Funded at University of Portland · NIH-10515248 · Data updated 2026-11-12
This study is looking at how certain prostate cancer treatments affect the immune system, specifically T cells, to find ways to make cancer therapies work better, especially for patients with prostate and breast cancers.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Portland NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 5, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $404,168 |
| NIH project number | 1R15CA267840-01A1 |
| Project ID | NIH-10515248 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include men with prostate cancer and women with androgen receptor positive breast cancer who are receiving or have received androgen deprivation therapy.
✕Less likely to help
Patients who do not have prostate cancer or androgen receptor positive breast cancer may not benefit from this research.
What this research studies
This research investigates the impact of androgen receptor antagonists, commonly used in prostate cancer treatment, on the function of human T cells. By understanding how these therapies influence immune responses, the study aims to uncover mechanisms that could enhance the effectiveness of cancer treatments, particularly immunotherapy. The research will involve analyzing T cell behavior in patients undergoing androgen deprivation therapy, which is crucial for improving treatment strategies for prostate and breast cancers. The findings could lead to better combination therapies that leverage the immune system to fight cancer more effectively.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment options that enhance immune responses in patients undergoing androgen deprivation therapy.
How similar studies have gone: Previous research has shown promising results in combining immunotherapy with androgen deprivation therapy, indicating that this approach may lead to significant advancements in cancer treatment.
Where this research is happening
-
University of Portland
Portland, United States Active
Researchers
- Principal investigator: Murray, Susan E — University of Portland
- Study coordinator: Murray, Susan E
Related research
Other NIH-funded projects on the same topics.
-
Investigating a protein that helps control cell division and its role in cancer and birth defects
This study is looking at a protein called Haspin, which helps make sure our cells divide correctly, and it's for anyone interested in how new cancer treatments might work better by targeting this protein to kill cancer cells without hurting healthy ones.
-
Understanding how blood flow affects the development of coronary arteries
This study is looking at how blood flow affects the growth of coronary arteries in chick embryos, specifically how it influences the movement and development of certain cells, and it aims to help us understand how blood flow helps shape healthy arteries.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.